CHR. OLESEN PHARMACEUTICALS A/S: Financial statements 2019
CVR: 32090168
Source: annual report 2019, Danish Business Authority
01/10/2018 – 30/09/2019
CHR. OLESEN PHARMACEUTICALS A/S (CVR 32090168) has filed annual accounts for 2019. In 2019, the company reported a gross profit of EUR 1,069,171 and a net result of EUR 474,910 compared with EUR 95,831 the year before. That is an increase of 128.5% compared with the year before. Equity in the 2019 report amounted to EUR 444,408. The solvency ratio was 5.3%. The company had 1 employee in the financial year.
- Gross Profit
- EUR 1,069,171
- Profit/Loss
- EUR 474,910
- Equity
- EUR 444,408
- Total Assets
- EUR 8,388,357
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | 1.1M EUR | 475K EUR | 444K EUR | 1 |
| 2018 | - | 468K EUR | 96K EUR | -31K EUR | 1 |
| 2017 | - | 529K EUR | 128K EUR | -126K EUR | 1 |
| 2016 | - | 395K EUR | 21K EUR | -254K EUR | 1 |
| 2015 | - | 326K EUR | -130K EUR | -295K EUR | 1 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
CHR. OLESEN PHARMACEUTICALS A/S has published its annual report for 2018. Gross profit came to DKK 467,859, and the net result was DKK 95,831.
About CHR. OLESEN PHARMACEUTICALS A/S
CHR. OLESEN PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Gentofte, founded in 2009. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Christian Dam Olesen, Mads Christian Olesen and Phillip Christian Dam Quitzau Olesen. The board consists of Tobias Facklam (chair), Christian Dam Olesen and Fabian von Volkmann. The company is owned by CHR. OLESEN A/S and SVVF UG & Co. KG. The company has 2 employees (2026). In 2025, the company reported a gross profit of EUR 1,210,782 and a net result of EUR 237,447 compared with EUR 70,556 the year before. Equity in the 2025 report amounted to EUR 1,744,707.
